Author's response to reviews

Title: Personalized medicine in psoriasis: developing a genomic classifier to predict response to Alefacept

Authors:

MAYTE Suárez-Fariñas (farinam@mail.rockefeller.edu)
KEJAL R SHAH (kshah@mail.rockefeller.edu)
ASIFA S HAIDER (haiderasifa@hotmail.com)
JAMES G KRUEGER (kruegej@mail.rockefeller.edu)
MICHELLE A LOWES (lowesm@mail.rockefeller.edu)

Version: 4 Date: 29 June 2009

Author's response to reviews: see over
June 29, 2009

Dear Editors of BioMed Central Dermatology,

We are submitting a manuscript entitled “Personalized medicine in psoriasis: developing a genomic classifier to predict response to Alefacept”.

Genomic expression profiles have been successfully used for disease classification and to predict response to treatment. Our goal in this study was to generate a “genomic classifier”, a set of genes that could predict response to Alefacept in the treatment of psoriasis. We used a discriminant analysis method that performs sample classification from gene expression data.

Although our study was small, this demonstrates the principle that pre-treatment gene expression may predict response to treatment. We have insufficient RNA remaining from this study for further analyses, but this information could be used by others to develop prospective methods to predict response. Ultimately, these sorts of studies may be helpful to physicians in selecting psoriasis patients who could benefit from treatment with Alefacept.

All authors have read and approved all versions of the manuscript, its content, and its submission to the BMC dermatology.

Yours sincerely,

Michelle Lowes, MD. PhD
Laboratory for Investigative Dermatology
Rockefeller University
lowesm@rockefeller.edu
212-327-7576